A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Replay
Most Recent Events
- 03 Apr 2023 Status changed from recruiting to enrolment to completed.
- 09 Jan 2023 Planned End Date changed from 15 Dec 2023 to 15 Mar 2023.
- 09 Jan 2023 Planned primary completion date changed from 15 Dec 2022 to 28 Feb 2023.